Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease

NCT06976268 is registered in ClinicalTrials.gov with Biohaven Therapeutics Ltd. as lead sponsor.

NCT NCT06976268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06976268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants With Early Parkinson's Disease
Lead sponsor
Biohaven Therapeutics Ltd.
Phase
Phase 2/3
Overall status
Recruiting
Start date
May 28, 2025
Completion date
September 30, 2028
Enrollment
550 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease